Financials

v3.6.0.2
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 24,203 $ 24,991
Marketable securities 36,832 62,263
Prepaid expenses and other current assets 628 432
Total current assets 61,663 87,686
Property and equipment and other assets, net 272 223
Total assets 61,935 87,909
Current liabilities:    
Accounts payable 1,921 994
Accrued direct program expenses 2,646 1,555
Accrued employee benefits 1,879 1,675
Accrued other liabilities 53 195
Total current liabilities 6,499 4,419
Commitments and contingencies
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value; 10,000,000 shares authorized for both periods presented; no shares issued and outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized for both periods presented; 15,565,973 and 15,462,030 shares issued and outstanding, respectively 16 15
Additional paid-in capital 235,737 232,309
Accumulated other comprehensive income (loss) (17) 3
Accumulated deficit (180,300) (148,837)
Total stockholders' equity (deficit) 55,436 83,490
Total liabilities and stockholders' equity (deficit) $ 61,935 $ 87,909

Source

v3.6.0.2
Statements of Operations and Comprehensive Loss
$ in Thousands
12 Months Ended
Dec. 31, 2014
USD ($)
$ / shares
shares
Operating expenses:  
Research and development $ 12,200
General and administrative 2,287
Loss from operations (14,487)
Interest and other income, net 296
Interest expense (845)
Net loss (15,036)
Gain on extinguishment of convertible debt as a capital transaction 378
Net loss attributable to common stockholders (14,658)
Comprehensive loss $ (14,658)
Weighted average shares outstanding - basic and diluted (in shares) | shares 723
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) | $ / shares $ (20.27)

Source

v3.6.0.2
Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities      
Net loss $ (31,463) $ (22,818) $ (15,036)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and loss on disposal of assets 143 66 88
Stock-based compensation expense 3,263 1,343 70
Change in value of preferred stock warrant liabilities and derivative     (296)
Amortization of deferred financing costs and noncash interest     708
Changes in operating assets and liabilities:      
Prepaid expenses and other (282) 198 (380)
Accounts payable 927 65 258
Accrued direct program expenses 1,091 311 355
Accrued employee benefits 204 1,465 (183)
Accrued other liabilities (142) 163 (32)
Net cash used in operating activities (26,259) (19,207) (14,448)
Investing activities      
Purchases of property and equipment (106) (188) (4)
Purchases of marketable securities (75,324) (76,260)  
Proceeds from maturities and sales of marketable securities 100,735 14,000  
Net cash provided by (used in) investing activities 25,305 (62,448) (4)
Financing activities      
Proceeds from issuance of common stock, net of offering costs 20 78,771  
Proceeds from issuance of common stock under employee share plans 146 63 2
Proceeds from issuance of convertible preferred stock, net     29,935
Decrease in restricted cash     2,500
Proceeds from notes payable, net     11,868
Principal payment on debt     (3,139)
Net cash provided by financing activities 166 78,834 41,166
Net increase (decrease) in cash and cash equivalents (788) (2,821) 26,714
Cash and cash equivalents, beginning of period 24,991 27,812 1,098
Cash and cash equivalents, end of period $ 24,203 24,991 27,812
Supplemental disclosures of cash flow information      
Cash paid for interest     165
Conversion of convertible preferred stock to common stock   $ 41,880  
Conversion of convertible debt and accrued interest to convertible preferred stock, net     $ 24,655

Source

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.